The Ministry of Health, Labor and Welfare (MHLW) on December 12 presented a draft outline of the FY2026 drug pricing…
REGULATORY
Chuikyo to Discuss “Price-Setting Including NHI Price Increases” Using Cost-Effective Assessments
The Central Social Insurance Medical Council’s (Chuikyo) subcommittee on cost-effective assessments agreed at a meeting on November 30 to discuss “price-setting that includes increases as well as decreases in the NHI prices of products after their launch” as a result…
To read the full story
Related Article
- HIV Combo Pill Prezcobix OK’ed for NHI Price Listing
December 1, 2016
- Industry, Healthcare Provider Reps Oppose “Annual Revisions” as Payers Hold Off Stance: Chuikyo
December 1, 2016
- Chuikyo at Odds over Price Maintenance Premium
December 1, 2016
- Annual Price Revision Push Gaining Momentum; PM Wants Pricing Revamp Policy by Year-End
November 28, 2016
- Chuikyo OKs 7 Drugs Subject to Cost-Effective Review; Re-Pricing to Be Conducted in 2018
April 27, 2016
REGULATORY
- Japan Puts CEA Expansion on Hold, Sets 6-Month “Technical Discussions”
December 26, 2025
- Gist of FY2026 Drug Pricing Reform Outline
December 26, 2025
- Chuikyo OKs FY2026 Drug Pricing Reform Outline, Scraps “Spillovers” but Adds New Follow-Up Rules
December 26, 2025
- Japan Cabinet OKs Record Social Security Spending in FY2026 Budget, 105 Billion Yen in Drug Price Cuts
December 26, 2025
- MHLW Names 77 Active Ingredients for OTC-Like Drug Charges
December 26, 2025
Let’s ditch the stuffy jargon and talk about AI in HR like real humans.One of the biggest myths floating around is that AI is coming to steal our jobs. Newsflash: that’s not happening. Sure, AI can handle the boring stuff…
Novartis’ Pluvicto (lutetium vipivotide tetraxetan (177Lu)) won reimbursement listing in Japan in November as a radioligand therapy (RLT) for PSMA-positive…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…